Currently, sotorasib (AMG510) is approved by the FDA as a second-line treatment for patients with KRAS-G12C-mutant NSCLC who have received at least one systemic therapy (13, 14). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.